Anne K. Mühlig

Dr. Anne K. Mühlig


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAnne K. Mühlig
Anne K. Mühlig
JLJun Young Lee
Jun Young Lee
MKMarkus J. Kemper
Markus J. Kemper
Andreas KronbichlerAndreas Kronbichler
Andreas Kronbichler
JYJaewon Yang
Jaewon Yang
JOJun Dr. Oh
Jun Dr. Oh
Steroid sensitive nephrotic syndrome is one of the most common pediatric glomerular diseases. Unfortunately, it follows a relapsing and remitting course in the majority of cases, with 50% of all cases relapsing once or even more often. Most children with idiopathic nephrotic syndrome respond initially to steroid therapy, nevertheless repeated courses for patients with relapses induce significant steroid toxicity. Patients with frequent relapses or steroid dependency thus require alternative treatment, such as cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, levamisole, or rituximab. To reduce the relapse rate, several drugs have been used. Among these, levamisole has been considered the least toxic and least expensive therapy. Several randomized controlled trials (RCT) showed that levamisole is effective in reducing the relapse risk in steroid sensitive forms of nephrotic syndrome with a low frequency of side effects. Levamisole is a synthetic imidazothiazole derivative with immune-modulatory properties. In this article, we review recent data from randomized trials and observational studies to assess the efficacy of levamisole in frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome.

23 September 2025 in JCI Insight
Verified
Journal Article
Open access
JCJan Czogalla
Jan Czogalla
FHFabian Hausmann
Fabian Hausmann
SLSimon Lagies
Simon Lagies
SGSydney E. Gies
Sydney E. Gies
SCSabrina Christiansen
Sabrina Christiansen
VPVictor G. Puelles
Victor G. Puelles
Normothermic machine perfusion (NMP) has become a valuable tool to expand the pool of transplantable organs. However, the application of NMP to kidneys presents substantial challenges, mostly due to high variability in the composition of currently used perfusion solutions. Here, we provide a multimodal cross-species cellular atlas of kidney injury associated with NMP using a literature-based consensus buffer. This resource provided a systematic framework that was used to develop a metabolite-enhanced perfusion solution, which protected renal proximal tubular cells, improving cellular viability and transplantation outcomes across species, including human kidneys.

21 February 2023 in Kidney International
Verified
Journal Article
Closed access
AMAnne K. Mühlig
Anne K. Mühlig
JOJun Oh
Jun Oh
THTobias B. Huber
Tobias B. Huber

18 January 2024 in Kidney International
Verified
Journal Article
Closed access
AMAnne K. Mühlig
Anne K. Mühlig
CSClaus-Peter Schmitt
Claus-Peter Schmitt
JOJun Oh
Jun Oh